Advertisement

Topics

Companies Related to "ConvaTec announces resignation chief executive issues profit warning" [Most Relevant Company Matches] RSS

04:30 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "ConvaTec announces resignation chief executive issues profit warning" found in our extensive corporate database of over 50,000 company records.

Showing "ConvaTec announces resignation chief executive issues profit warning" Companies 1–25 of 2,400+

Extremely Relevant

ConvaTec Healthcare

ConvaTec is a leading developer and marketer of innovative medical technologies. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. From its operational headquarters in Skillman, New ...


ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business divisions - Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices - ConvaTec products support health care professionals from the hospital to the community health setting. From its headquarters in Skil...

Relevant

THE MILES PARTNERSHIP

The Miles Partnership provides executive search services to UK and international clients across a range of sectors.The firm comprises five partners and is supported by an outstanding research team. The Miles partnership works at the highest levels of industry, recruiting chairmen, Chief Executive Partnership works at the highest levels of industry, recuiting Chairmen, Chief Executive Officers, Dir...


Sucampo Pharmaceuticals, Inc. and Numab AG

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company based in Bethesda, Maryland, is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids wa...

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified ...

Sucampo Pharmaceuticals, Inc. and Takeda

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company, is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuj...

Interface Biologics

Toronto, Canada – August 26, 2005 - Interface Biologics Inc. announced today the appointment of Richard W. Sullivan to the position of President and Chief Executive Officer of the Company.Mr. Sullivan brings more than 30 years of senior management and executive experience in the life sciences industry, having held key positions in early stage corporations since 1990. Most recently, as Chief Exec...

Advanced Warning Systems, Inc.

Advanced Warning Systems, Inc., a disease management and healthcare services company, is headquartered in Carlsbad, California. The company’s unique healthcare service solutions utilize wired and wireless technology devices that satisfy compliance and ease of use requirements to improve patient outcomes. Advanced Warning Systems is committed to patien...

AmeriLithium Corp.

Matthew Worrall, Chief Executive Officer

Vantage Oncology, LLC

Founded in October 2002, Manhattan Beach, California-based Vantage Oncology, LLC owns, operates and manages radiation oncology centers of excellence. The company’s founding principles were to address the growing need among cancer patients, hospitals and physicians for easily accessible and advanced radiation treatment therapies. Vantage Oncology curre...

Sucampo Pharmaceuticals, Inc. and Abbott

Sucampo Pharmaceuticals, Inc., an international biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymic (15-PGDH) transformation of certain fatty acids, was first identified ...

Partnership Fund for New York City

The Partnership Fund for New York City is the $115 million investment arm of the Partnership for New York City (www.pfnyc.org). The Fund’s mission is to engage the City’s business leaders to identify and support promising NYC-based entrepreneurs in both the for-profit and non-profit sectors to create jobs, spur new business, and expand opportunit...

Vantage Oncology

Founded in October 2002, Vantage Oncology acquires, joint ventures, develops and operates radiation oncology centers of excellence. The Company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Recent developments at Vantage include the establishment of multi-specialty oncology care organizations ...

Medivizor

Medivizor offers a patent-pending, personalized health information platform for individuals with serious or chronic illnesses. Users of Medivizor are benefiting from custom content, cutting-edge research, clear and authoritative descriptions of treatment options, individual-matched clinical trials, social engagement, and much more. Professor Steven ...

Vmersion-Health

Vmersion-Health, developer of Gluco-Share, is a California Limited Partnership founded in 2011. Vmersion-Health develops and publishes social media applications for health-related causes, with a commitment to improved health through better communication and social support mechanisms. Joseph “Joe” Madden is president and Chief Executive Officer; J...

Origo Acquisition Corporation

Origo Acquisition Corporation is a public investment vehicle formed for the purpose of effecting a merger, acquisition or similar business combination. Origo is led by Chief Executive Officer Edward J. Fred, Chief Financial Officer Jose M. Aldeanueva and Directors Stephen B. Pudles, Jeffrey J. Gutovich and Barry Rodgers. Origo’s securities are quoted ...

REVOLUTION Medicines

The REVOLUTION Medicines team brings deep expertise and a track record of building exceptional life sciences companies. In addition to Dr. Goldsmith, founding president and chief executive officer and Dr. Burke, founder and scientific advisory board chairman, the team includes: David Pompliano, Ph.D., founding chief scientific officer, who is a leading ...

CreAgri, Inc.

Dr. Roberto Crea Moves to Chairman and Donald Ladwig Named CEO (Hayward, CA). CreAgri Inc., President and founder, Dr. Roberto Crea, announced that Donald Ladwig has assumed the duties as President and Chief Executive Officer of CreAgri Inc. and its subsidiary Supremo Extra Virgin Olive Oil. Dr. Crea will remain with the corporation as Chairman of the Board and Chief Scientist.

The CATalyst Council

The 2009 CATalyst Council board of directors includes: Dr. Jane E. Brunt as executive director; Dan Kramer, senior marketing manager of industry relations, Pfizer Animal Health, as chair; Robert Rohde, president, Dumb Friends League, as vice chair; Dr. Alexis Nahama, vice president of marketing, VCA Animal Hospitals, as secretary; and Dr. Karen Felsted, chief executive officer, National Commission...

MedDay

MedDay is a privately held biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer), a leading neurologist and neuroscientist; and Guillaume Brion, MD (Chief Operating Officer) who has 25 years of experience in drug development and clinical research i...

Harbinger Capital Partners

Harbinger Capital Partners is a multi-billion dollar private investment fund based in New York which employs a fundamental, intensive research-based approach to investing. Harbinger Capital Partners is led by Phil Falcone who has been the Chief Executive Officer and Chief Investment Officer of funds affiliated with or managed by Harbinger Capital Partners ...

IntraBiotics Pharmaceuticals Inc.

On June 20, 2005, IntraBiotics Pharmaceuticals, Inc. announced that the Company was terminating all regular employees and ceasing all operations. It was also announced that the Company was appointing Hickey & Hill, Inc. to assume responsibilities for the day-to-day administration of the Company and that Mr. Hickey was to be designated Chief Executive Officer. Mr. Hickey has since been appointed Ch...

Greater Medical Center Group

The Greater Medical Center Group (GMCG) is a provider of U.S. Clerkships for International Medical Students and Graduates. As a network of professionals and educators, GMCG's mission is to standardize the clinical experience of medical students educated abroad while providing support services to international medical schools. Key executives are Dr. Stephen M. Cohen, Chief Executive Officer; ...

Baker Marquart LLP on behalf of Federico Pignatelli

Mr. Pignatelli served on the BIOLASE Board of Directors continuously from 1991 through August 2014 and is currently the beneficial owner of approximately 1.8 million shares of BIOLASE common stock. He served as Executive Chairman from 1994 through 2006. He was Chairman Emeritus from March 2006 to July 2010. He served as Chairman of the Board and as Chief E...

J.D. Kleinke

J.D. Kleinke is a medical economist, author, and health information technology executive. He currently serves as Chairman and Executive Director of Omnimedix Institute, a non-profit health care information technology research and development organization based in Portland, Oregon, and as Vice Chairman of HealthGrades, a publicly traded health care information company based in Denver.During the 199...


More From BioPortfolio on "ConvaTec announces resignation chief executive issues profit warning"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks